Skip to content
The Policy VaultThe Policy Vault

Braftovi (encorafenib) — Medica

Melanoma

Initial criteria

  • age ≥ 18 years
  • patient has unresectable, advanced, or metastatic melanoma
  • patient has BRAF V600 mutation-positive disease

Approval duration

1 year